Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622
This examiner grants 86% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18288550 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18706490 | LYSOPHOSPHATIDYLCHOLINE COMBINATIONS AS A THERAPY TO TREAT CARDIAC ARREST | Non-Final OA | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH |
| 18530775 | SILYL-BIARYL PHOSPHORAMIDITES AND METHODS OF MAKING | Non-Final OA | Board of Regents, The University of Texas System |
| 18531281 | TREATMENT OF INFECTIONS AND BIOFILM FORMATION USING A CELLULOSE SYNTHASE INHIBITOR | Non-Final OA | Purdue Research Foundation |
| 17763798 | COMPOSITIONS AND METHODS FOR PREVENTING AND/OR REDUCING WEIGHT GAIN AND ASSOCIATED CONDITIONS | Final Rejection | University of Virginia Patent Foundation |
| 18713428 | OIL-BASED COSMETIC | Non-Final OA | SHISEIDO COMPANY, LTD. |
| 18025315 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18572342 | PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | Non-Final OA | Celgene Corporation |
| 17597631 | PROTEIN DEGRADERS AND USES THEREOF | Final Rejection | Kymera Therapeutics, Inc. |
| 18269080 | METHODS OF TREATING MENTAL OR MOOD DISORDERS USING 2-BROMO-LSD | Non-Final OA | BETTERLIFE PHARMA INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy